top of page
Medical Checkup

ARRIVAL

Trial Enrolment Status

OPEN

Disease Under Study

ASTHMA

Duration

72 Weeks

About the Trial

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Mechanism of Action:

Anti-TSLP

Dr. George Philteos

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Hannah Harrison

bottom of page